http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0061116-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d05753be724a9852cff867dbb6df7f05
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-431
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
filingDate 2000-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba65e338e551425a6f349798f6f39d95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d0c82374b2edb98d6691d47b5707727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aa4a184aa83b733ceded793ad076173
publicationDate 2001-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0061116-A3
titleOfInvention Pharmaceutical formulation comprising amoxycillin and clavulanate
abstract Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8889187-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9144548-B2
priorityDate 1999-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9835672-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9219227-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4282202-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0012088-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9528148-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9842311-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9840054-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9709042-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9115197-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9427600-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9520946-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395608
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33613
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397639
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280980

Total number of triples: 50.